Hopkinton, MA – May 8, 2025 – In a groundbreaking collaboration, Phosphorex, NOFCORPORATION, NeoSome Life Sciences, NanoImaging Services (NIS), and EnvolBiomedical have joined forces to establish the LNP Alliance, a strategicpartnership dedicated to advancing lipid nanoparticle (LNP) technology andaccelerating the development of next-generation therapeutics.
The LNP Alliance brings together deep scientificexpertise, proprietary lipid innovations, world-class formulation capabilitiesand analytical and drug efficacy services to support biopharma and biotechcompanies in overcoming drug development challenges. By combining forces, theLNP Alliance provides a comprehensive, end-to-end solution encompassing lipidsynthesis, formulation development, process optimization, analyticalcharacterization, and manufacturing support—enabling partners to efficientlymove from discovery to clinical success.
“The LNP Alliance represents a uniqueconvergence of industry leaders, each bringing specialized expertise to driveinnovation in LNP-based drug development,” said Jarlath Keating, CEO ofPhosphorex. “By working together, we provide a comprehensive solution thatallows our partners to develop more effective therapies, faster.”
As a unified force in LNP innovation, the LNPAlliance offers:
•Access to proprietary ionizable lipids andexcipients for optimized drug delivery
•Expert formulation and process development toenhance LNP stability and efficacy
•Integrated analytical and manufacturingcapabilities for streamlined scale-up
•Cryo-TEM imaging for nanoparticlecharacterization
•Biodistribution, efficacy, and toxicologyevaluations in multiple animal models, including Non-Human Primates
“With our extensive experience in lipidchemistry and drug delivery technologies, NOF is proud to be part of thistransformative initiative,” said Yuji Yamamoto, General Manager of NOFCORPORATION. “The LNP Alliance allows us to collaborate closely with industrypartners to advance new therapeutics and bring real value to patients.”
The launch of the LNP Alliance underscores thecommitment of Phosphorex, NOF CORPORATION, NeoSome Life Sciences, NIS and EnvolBiomedical to shaping the future of LNP-based drug development. Together, theyare driving innovation, accelerating timelines, and empowering biopharmacompanies to bring groundbreaking treatments to patients in need.
For more information on the LNP Alliance andpartnership opportunities, please email LNPalliance@phosphorex.com
About the LNP Alliance Partners
Phosphorex – A leading CRO / CDMO specializing in drug delivery, offeringexpertise in LNP formulation, process development, scale-up and analytics. Formore info, visit www.phosphorex.com
NOF CORPORATION – A global pioneer in PEG and lipid chemistry,providing high-performance ionizable lipids, PEG lipids, and excipients foradvanced drug delivery applications. For more info, visit www.dds-drug.com
NeoSome Life Sciences – An innovative preclinical CRO providingcomprehensive in vitro and in vivo services tosupport drug discovery anddevelopment across various therapeutic areas. For more info, visit www.neosomels.com
NanoImaging Services – A leader in cryo-electron microscopy (cryo-EM) andnanoparticle characterization, ensuring the highest quality and integrity forLNP-based therapeutics. For more info, visit www.nanoimagingservices.com
Envol Biomedical – A leading non-clinical laboratory offeringpharmacology and toxicology capabilities focused on Non-Human Primates. Formore info, visit www.envolbio.com
Welcome to Finsweet's accessible modal component for Webflow Libraries. This modal uses Webflow Interactions to open and close. It is accessible through custom attributes and custom JavaScript added in the embed block of the component. If you're interested in how this is built, check out the Attributes documentation page for this modal component.
Infographic Available for Download
Phosphorex, NOF CORPORATION, NeoSome Life Sciences, NIS, and Envol Biomedical Unite to Form the LNP Alliance—Accelerating Lipid Nanoparticle Drug Development